<DOC>
	<DOCNO>NCT01511185</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial ass effect NNC 90-1170 beta-cell responsiveness increase blood glucose concentration subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Liraglutide Beta-cell Responsiveness Subjects With Type 2 Diabetes Compared Healthy Control Group</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed type 2 diabetes , either newly diagnose least 2 month diet OAD monotherapy least 3 month Body Mass Index ( BMI ) : 2435 kg/m^2 inclusive SUBJECTS WITH TYPE 2 DIABETES Receipt investigational drug within three month prior trial Recurrent severe hypoglycemia judge investigator Cardiac disease Use drug ( except OAD ( oral antidiabetic drug ) ) investigator 's opinion could interfere blood glucose level Haemoglobin maximum 10 g/L HbA1c 12 % Loss 400 mL blood 3 month prior trial start HEALTHY SUBJECTS Receipt investigational drug within 3 month prior trial Clinically relevant cardiac disease clinically significant abnormal ECG ( electrocardiogram ) Use drug investigator 's opinion could interfere blood glucose level Haemoglobin max . 10 g/L HbA1c least 6 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>